

Damon Runyon Cancer Research Foundation and Berlex Oncology Partner To Spark Early Career Cancer Investigators

Dateline, August, 2005 –The Damon Runyon Cancer Research Foundation today announced a new partnership with Berlex, Inc., a U.S. affiliate of Schering AG, Germany (NYSE:SHR), to support outstanding young scientists committed to understanding cancer and developing new approaches to prevention, diagnosis and treatment. Berlex Oncology has committed \$134,000 over three years to support the Damon Runyon Fellowship Award, which funds postdoctoral fellowships for junior investigators working in leading academic research laboratories across the United States and internationally. These highly prestigious awards are designed to recruit top young scientists into cancer research and to enable them to explore innovative areas of research.

The Berlex support will be used to fund Don X. Nguyen, PhD, a postdoctoral fellow in the laboratory of Joan Massagué, PhD, Program Chairman of Cell Biology and Genetics at Memorial Sloan-Kettering Cancer Center. Dr. Nguyen's research focuses on breast cancer and understanding the genetic basis of its often-lethal spread (metastasis) to the lung. He has been named the Berlex Fellow of the Damon Runyon Cancer Research Foundation in recognition of Berlex's support.

"Dr. Nguyen, as a Berlex Fellow, becomes a member of the elite corps of Damon Runyon scientists devoted to understanding and eradicating cancer. He joins our own Dr. Mark Gilbert, who heads cancer clinical development at Berlex, and who began his career as a Damon Runyon scientist. We are very proud to continue this commitment to basic research in cancer," said Dr. Marc Rubin, who leads global pharmaceutical development and is a member of the Schering AG Germany Board of Executive Directors.

About Berlex

Berlex, Inc., a U.S. affiliate of Schering AG, Germany (NYSE:SHR), is committed to developing novel diagnostics and therapeutics that address unmet medical needs. Berlex develops and markets diagnostic imaging agents, treatments in the areas of female healthcare and oncology, as well as specialized therapeutics for life-threatening and disabling diseases in the fields of the central nervous system and gastroenterology. Berlex has business operations in New Jersey, California and Washington. For more information, please visit www.berlex.com.

About the Damon Runyon Cancer Research Foundation

Founded in 1946, the Damon Runyon Cancer Research Foundation focuses on identifying extraordinary young scientists and encouraging them to focus their research on the complex challenges of cancer. The Foundation is dedicated to launching the careers of generations of truly innovative investigators in cancer research—scientists that approach questions from totally new directions and challenge existing dogma. To date, the Damon Runyon Cancer Research Foundation has invested over \$170 million in cancer research, supporting more than 3,000 of the most gifted researchers in the nation. Damon Runyon scientists and physician-scientists, in leadership roles in the world's major research institutions and cancer centers, have made breakthrough discoveries that have and will continue to save countless lives. For more information, please visit www.drcrf.org.

###